Overview

Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

Status:
Active, not recruiting

Trial end date:
2021-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of olaparib versus enzalutamide or abiraterone acetate in subjects with metastatic castration-resistant prostate cancer who have failed prior treatment with a new hormonal agent and have homologous recombination repair gene mutations.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Collaborators:

Foundation Medicine, Inc.
Merck Sharp & Dohme Corp.
Myriad Genetics, Inc.

Treatments:

Abiraterone Acetate
Olaparib